These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7272165)

  • 1. Comparison of the duration of effect of metoprolol and a sustained release formulation of metoprolol (betaloc-SA).
    Harron DW; Shanks RG
    Br J Clin Pharmacol; 1981 May; 11(5):518-20. PubMed ID: 7272165
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma levels and negative chronotropic effect of metoprolol following single doses of a conventional and sustained release formulation.
    Piercy DA
    Eur J Clin Pharmacol; 1979 Sep; 16(3):219. PubMed ID: 499324
    [No Abstract]   [Full Text] [Related]  

  • 3. The comparative beta-adrenoceptor blocking effects of penbutolol, atenolol and sustained-release metoprolol in healthy volunteers.
    Mucklow JC; Kuhn S
    Eur J Clin Pharmacol; 1984; 27(3):269-73. PubMed ID: 6510453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maximal exercise power after a single dose of metoprolol and of slow-release metoprolol.
    Folgering H; van Bussel M
    Eur J Clin Pharmacol; 1980 Oct; 18(3):225-9. PubMed ID: 7439241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects on exercise tachycardia during forty-eight hours of a series of doses of atenolol, sotalol, and metoprolol.
    Harron DW; Balnave K; Kinney CD; Wilson R; Russell CJ; Shanks RG
    Clin Pharmacol Ther; 1981 Mar; 29(3):295-302. PubMed ID: 7471600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma levels and negative chronotropic effect of metoprolol following single doses of a conventional and sustained-release formulation.
    Quaterman CP; Kendall MJ; Welling PG
    Eur J Clin Pharmacol; 1979 Mar; 15(2):97-103. PubMed ID: 436924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the pharmacodynamic and pharmacokinetic profiles of single and multiple doses of a commercial slow-release metoprolol formulation with a new Oros delivery system.
    Kendall MJ; Jack DB; Woods KL; Laugher SJ; Quarterman CP; John VA
    Br J Clin Pharmacol; 1982 Mar; 13(3):393-8. PubMed ID: 7059440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing.
    Freestone S; Silas JH; Lennard MS; Ramsay LE
    Br J Clin Pharmacol; 1982 Nov; 14(5):713-8. PubMed ID: 7138751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative bioavailability and effect studies on metoprolol administered as ordinary and slow-release tablets in single and multiple doses.
    Regårdh CG; Johnsson G; Jordö L; Sölvell L
    Acta Pharmacol Toxicol (Copenh); 1975; 36(Suppl 5):45-58. PubMed ID: 1079687
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic comparison of a new controlled-release formulation of metoprolol with a traditional slow-release formulation.
    Oosterhuis B; Jonkman JH; Kerkhof FA
    Eur J Clin Pharmacol; 1988; 33 Suppl():S15-8. PubMed ID: 3371389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative activity of atenolol and metoprolol.
    Harry JD; Shields AG
    Br Med J; 1978 Jul; 2(6130):128. PubMed ID: 352474
    [No Abstract]   [Full Text] [Related]  

  • 12. Plasma levels and beta-blocking effect of alpha-hydroxymetoprolol--metabolite of metoprolol--in the dog.
    Regårdh CG; Ek L; Hoffmann KJ
    J Pharmacokinet Biopharm; 1979 Oct; 7(5):471-9. PubMed ID: 43384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow-release metroprolol.
    Kendall MJ; John VA; Quarterman CP; Welling PG
    Eur J Clin Pharmacol; 1980 Feb; 17(2):87-92. PubMed ID: 7371709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The actions of the beta-adrenoceptor blocking agents propranolol and metoprolol in the maximally exercised horse [proceedings].
    Snow DH; Summers RJ
    J Physiol; 1977 Oct; 271(2):39P-40P. PubMed ID: 925991
    [No Abstract]   [Full Text] [Related]  

  • 15. Plasma levels and pharmacological effects of metoprolol administered as controlled release (Durules) and ordinary tablets in healthy volunteers.
    Johnsson G; Jordö L; Lundborg P; Regårdh CG; Rönn O
    Int J Clin Pharmacol Ther Toxicol; 1980 Jul; 18(7):292-7. PubMed ID: 7000717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure of propranolol and metoprolol to alter ventilatory responses to carbon dioxide and exercise.
    Leitch AG; Hopkin JM; Ellis DA; Clarkson DM; Merchant S; McHardy GJ
    Br J Clin Pharmacol; 1980 May; 9(5):493-8. PubMed ID: 6772199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained release metoprolol: a comparison with conventional formulation in the treatment of hypertension.
    Logan RL; Goldstraw PW; Kiddle GB; Flacks LM; Watt M
    N Z Med J; 1981 Jul; 93(687):1-2. PubMed ID: 7022275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardioselective (metoprolol) and non-selective (propranolol) beta-blockade and glucose homeostasis.
    Syvälahti E; Lammintausta R; Iisalo E; Kanto J
    Ann Clin Res; 1977 Oct; 9(5):292-5. PubMed ID: 616215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacokinetic comparison between different slow-release formulations of metoprolol (Lopresor SR and Betaloc SA).
    Browning RC; John VA; Till RJ; Theobald W
    Br J Clin Pharmacol; 1981 Oct; 12(4):600-2. PubMed ID: 7295497
    [No Abstract]   [Full Text] [Related]  

  • 20. Metoprolol administered once daily in the treatment of hypertension. A double-blind crossover comparison between conventional tablets and metoprolol Durules.
    Asplund J; Ohman P
    Ann Clin Res; 1981; 13 Suppl 30():30-6. PubMed ID: 7027891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.